Tornesello Maria Lina, Buonaguro Luigi, Izzo Francesco, Buonaguro Franco M
Molecular Biology and Viral Oncology Unit, Department of Research, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Napoli, Italy.
Hepato-Biliary Surgery Department, Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, Napoli, Italy.
Oncotarget. 2016 May 3;7(18):25087-102. doi: 10.18632/oncotarget.7837.
Chronic infections with hepatitis B (HBV) and hepatitis C viruses (HCV) are the leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide. Both viruses encode multifunctional regulatory proteins activating several oncogenic pathways, which induce accumulation of multiple genetic alterations in the infected hepatocytes. Gene mutations in HBV- and HCV-induced HCCs frequently impair the TP53, Wnt/b-catenin, RAS/RAF/MAPK kinase and AKT/mTOR pathways, which represent important anti-cancer targets. In this review, we highlight the molecular mechanisms underlying the pathogenesis of primary liver cancer, with particular emphasis on the host genetic variations identified by high-throughput technologies. In addition, we discuss the importance of genetic alterations, such as mutations in the telomerase reverse transcriptase (TERT) promoter, for the diagnosis, prognosis, and tumor stratification for development of more effective treatment approaches.
慢性乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染是全球肝硬化和肝细胞癌(HCC)的主要病因。两种病毒都编码多功能调节蛋白,激活多种致癌途径,导致受感染肝细胞中多种基因改变的积累。HBV和HCV诱导的肝癌中的基因突变经常损害TP53、Wnt/β-连环蛋白、RAS/RAF/MAPK激酶和AKT/mTOR途径,这些途径是重要的抗癌靶点。在本综述中,我们重点介绍原发性肝癌发病机制的分子机制,特别强调通过高通量技术鉴定的宿主基因变异。此外,我们讨论了基因改变的重要性,如端粒酶逆转录酶(TERT)启动子中的突变,对于诊断、预后以及肿瘤分层以开发更有效的治疗方法的重要性。